Psoriasis patients: does your injection schedule matter?

NCT ID NCT07642544

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 120 adults with moderate-to-severe psoriasis who take secukinumab, a biologic drug. It compares two maintenance schedules: the standard every-4-week injection versus a non-standard schedule (longer intervals or lower dose). The goal is to see which schedule keeps psoriasis under control longer and how well patients recover if the drug stops working. The study is observational and uses medical records, so it cannot prove cause and effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
secukinumab (a biologic drug that targets inflammation)
What this could lead to
If successful, this could help doctors choose the best maintenance schedule for secukinumab to keep psoriasis under control longer.
What could go wrong
This is a small, single-center retrospective study, not a randomized trial. Results may not apply to all patients, and the study only looks back at existing records.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School

    Nanjing, Jiangsu, 210008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.